Krónikus limfoid leukémia (CLL): vizsgálatok itt: Ausztrália
29 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Where
- Adelaide, Box Hill, Melbourne
- Életkor
- 18 év and over
- People
- 735 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05947851 · EU 2022-501560-17-00 - 1. fázisTaking peopleA Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Where
- East Melbourne, Melbourne, Woolloongabba
- Életkor
- 18 év and over
- People
- 332 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05091424 - 2. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Where
- Adelaide, Bankstown, Box Hill, Coffs Harbour, Hobart, Kurralta Park, Traralgon, Waratah, West Perth, Woolloongabba
- Életkor
- 18 év and over
- People
- 249 worldwide
- Run by
- Loxo Oncology, Inc.
See details and how to joinNCT06588478 · EU 2024-515689-15-01 - 1. fázisCsak meghívásosA Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
- Where
- Macquarie University, Melbourne, Nedlands, Randwick
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00 - 4. fázisTaking peopleA Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Where
- Melbourne
- Életkor
- 18 év and over
- People
- 150 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07218341 - 1/2. fázisTaking peopleA Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Where
- Heidelberg, Melbourne, Nedlands
- Életkor
- 18 év and over
- People
- 408 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06564038 · EU 2024-515034-33-00 - 2. fázisTaking peopleEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Where
- Box Hill, Nedlands, Sydney
- Életkor
- 18 év and over
- People
- 490 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04728893 · EU 2023-504931-42-00 - 1/2. fázisTaking peopleA Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Where
- Adelaide, Blacktown, Cooloongup, Malvern, Melbourne, Nedlands
- Életkor
- 18 év and over
- People
- 258 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06697184 · EU 2024-518829-15-00 - 3. fázisTaking peopleA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Where
- Birtinya, Blacktown, Clayton, Cooloongup, Fitzroy, Kogarah, Lismore, Melbourne, North Ryde, St Leonards, West Perth, Woolloongabba
- Életkor
- 18 év and over
- People
- 630 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06943872 · EU 2024-517131-52-00 - 1. fázisTaking peopleA Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- Where
- Fitzroy, Saint Leonards
- Életkor
- 18 év and over
- People
- 106 worldwide
- Run by
- Umoja Biopharma
See details and how to joinNCT06528301 - 3. fázisTaking peopleA Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Where
- St Leonards
- Életkor
- 18 év and over
- People
- 1200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136559 · EU 2022-501697-19-01 - 3. fázisTaking peopleSurovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Where
- Adelaide, Fitzroy, Heidelberg, Nedlands, Perth, Rockingham
- Életkor
- 18 év to 18 év
- People
- 420 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07509151 - 1/2. fázisTaking peopleA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Where
- Concord, Fitzroy, Heidelberg, Melbourne, Nedlands, Waratah, West Perth, Woolloongabba
- Életkor
- 18 év and over
- People
- 689 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00 - 1/2. fázisTaking peopleVenetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
- Where
- Melbourne
- Életkor
- 18 év and over
- People
- 112 worldwide
- Run by
- Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT05791409 · EU 2022-500305-40-00 - 1/2. fázisTaking peopleA Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Where
- Melbourne, Nedlands
- Életkor
- 18 év and over
- People
- 174 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06542250 - 3. fázisTaking peopleA Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Where
- Bedford PK, Concord, Gosford, Melbourne, Port Macquarie, Randwick, Toowoomba, West Perth
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06846671 · EU 2024-518893-15-00 - 3. fázisTaking peopleA Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Where
- Bedford PK, Benowa, Birtinya, Concord, Fitzroy, Frankston, Heidelberg, Kogarah, Malvern, Melbourne, Nedlands, Tugun, Westmead
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06973187 · EU 2025-522860-34-00 - 3. fázisTaking peopleA Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Where
- Blacktown, Clayton, Concord, Heidelberg, Malvern, Melbourne, St Leonards, Woolloongabba
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT07277231 · EU 2025-524366-21-00 - 1. fázisTaking peopleDose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Where
- Adelaide, Camperdown, Fitzroy, Geelong, Liverpool
- Életkor
- 18 év and over
- People
- 135 worldwide
- Run by
- Imugene Limited
See details and how to joinNCT03666000 - 2. fázisTaking peopleClonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib
- Where
- Melbourne
- Életkor
- 18 év and over
- People
- 40
- Run by
- Peter MacCallum Cancer Centre, Australia
See details and how to joinNCT06812715 - 3. fázisTaking peopleA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Where
- Nedlands, St Albans, West Perth
- Életkor
- 18 év and over
- People
- 737 worldwide
- Run by
- Loxo Oncology, Inc.
See details and how to joinNCT05254743 · EU 2023-507699-38-00 - 3. fázisTaking peopleGlobal Trial in APG2575 for Patients With CLL/SLL
- Where
- Gosford, Perth, Westmead
- Életkor
- 18 év to 99 év
- People
- 400 worldwide
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT06104566 · EU 2023-508005-24-00 - 3. fázisTaking peopleA Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Where
- Fitzroy, Perth, Townsville, Waratah
- Életkor
- 18 év and over
- People
- 170 worldwide
- Run by
- AbbVie
See details and how to joinNCT06428019 · EU 2024-512147-23-00 - 4. fázisTaking peopleA Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Where
- Adelaide, Melbourne, Victoria
- Életkor
- 18 év and over
- People
- 787 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06876649 - 4. fázisTaking peopleA Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Where
- Adelaide, Melbourne, Victoria
- Életkor
- 18 év and over
- People
- 279 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06876662